RTS, S/AS01 Malaria Vaccine: Efficacy, Implementation Challenges, and Public Health Impact

Irakoze Mukamana S.

School of Applied Health Sciences Kampala International University Uganda

                                                          ABSTRACT
Malaria remained a major global health burden, with Plasmodium falciparum causing significant morbidity and mortality, particularly among children in sub-Saharan Africa. The RTS, S/AS01 vaccine represents the first licensed malaria vaccine, targeting the circumsporozoite protein of the parasite’s pre-erythrocytic stage. This review critically examined the efficacy profile of RTS,S/AS01, evaluated implementation challenges encountered during pilot programs, and assessed the vaccine’s broader public health impact in endemic regions. A comprehensive literature search was conducted across PubMed, Scopus, and clinical trial registries, selecting peer-reviewed articles, systematic reviews, and implementation reports published between 2011 and 2025. Phase III trials demonstrated modest efficacy, with approximately 32% reduction in clinical malaria episodes among children aged 5 to 17 months over four years when administered in four doses. Pilot implementation programs in Ghana, Kenya, and Malawi revealed significant operational challenges, including maintaining cold chain integrity, achieving adequate coverage across four-dose schedules, and integrating delivery with existing immunization programs. Despite moderate efficacy, mathematical modeling indicates that RTS, S/AS01 deployment in high-transmission settings can avert substantial numbers of clinical cases and deaths when combined with existing vector control and chemoprevention strategies. Cost-effectiveness analyses suggested favorable outcomes in areas with persistent high transmission. Antibody responses wane substantially within 12 months post vaccination, raising questions about optimal booster timing and long-term protection. RTS, S/AS01 represented a significant milestone in malaria control, offering partial protection that complements existing interventions. Ongoing research must address immunological gaps, optimize delivery strategies, and monitor real-world effectiveness to maximize public health benefit.

Keywords: RTS, S/AS01 vaccine, Plasmodium falciparum, Malaria prevention, Circumsporozoite protein, Vaccine implementation.

CITE AS: Irakoze Mukamana S. (2026). RTS, S/AS01 Malaria Vaccine: Efficacy, Implementation Challenges, and Public Health Impact. Research Output Journal of Public Health and Medicine 6(1):92-99. https://doi.org/10.59298/ROJPHM/2026/619299